
Enigma Biomedical USA’s Tau PET Alzheimer’s Drug NDA Accepted by FDA
Enigma Biomedical USA Announces FDA Acceptance of New Drug Application for Tau PET Radiodiagnostic MK-6240 in Alzheimer’s Diseas Biomedical USA (EB USA) today announced that the U.S. Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA)…








